\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Effectiveness of Perineural Dexmedetomidine and Ropivacaine on Preventing Phantom Limb Pain in Patients Undergoing Femoral Supracondylar Amputation}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2020 2020-01-15 (revised: 17 Year 2020 15 January 2020)} \def\TheID{\makeatother } \def\TheDate{2020 2020-01-15} \title{Effectiveness of Perineural Dexmedetomidine and Ropivacaine on Preventing Phantom Limb Pain in Patients Undergoing Femoral Supracondylar Amputation} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{ Ramirez-Jaime} \author[2]{ Estrada-Sara} \author[3]{ Martinez-Raquel} \affil[1]{ University of Guadalajara} \renewcommand\Authands{ and } \date{\small \em Received: 7 December 2019 Accepted: 1 January 2020 Published: 15 January 2020} \maketitle \begin{abstract} Background: Phantom limb pain is a frequent complication after limb amputation, its pathophysiology is complex and includes changes in the peripheral nerve, dorsal root ganglia, spinal cord, cerebral cortex, and thalamus. At this time, there is not an effective drug for treatment and prevention of phantom limb pain. Perineural local anesthetic infiltration has obtained different results in the prevention of phantom limb pain, so we propose to combine an ?2 agonist in peripheral nerve block to assess its effectiveness in preventing postoperative pain. Methods: This was a prospective, double-blind, controlled, and simple randomized study. We included 30 patients undergoing surgery for supracondylar femoral amputation, older than 18 years, ASA I-III, in a sample calculation of 95% in Confidence Interval and 80% of statistical power. We included 15 patients per group managed with subarachnoid neuraxial block, and a perineural infiltration before the sciatical nerve section with 10 ml of 0.5% ropivacaine + 50 mcg dexmedetomidine (RD Group), or 0.5% ropivacaine + 0.9% saline solution (Group RS), in both groups We continued a perineural infusion with 0.15% ropivacaine using an elastomeric pump for 24 hours; We evaluated stump pain and phantom limb pain, upon admission to recovery, 8 hrs, 24 hrs, 30 days and 3 months. The data analysis was carried out using the SPSS version 21 program; In all cases, we defined statistical significance when obtaining p <0.05. Results: This study included a total of 30 patients, 15 patients in the RD group and 15 patients in the RS group. Statistical significance was found in the pain levels of the stump at rest at 24 hours, being lower in the RD group (p = 0.003). This intervention also impacted the opioid requirements at 24 hours, requiring tramadol rescue 27% of the patients in the RD group, against 93% of the patients in the RS group (p = 0.0002). Regarding phantom limb pain, there was no incidence during the three months of follow-up in the RD group, against three patients who report mild phantom limb pain in the RS group. Conclusions: The combination of ropivacaine with dexmedetomidine appears to be an effective intervention with minimal side effects to prevent the occurrence of acute and chronic pain as well as phantom limb pain in patients undergoing femoral supracondylar amputation as well as reducing the postoperative opioid requirements. \end{abstract} \keywords{phantom limb pain, analgesia, dexmedetomidine, periferial nerve block, supracondylar amputation.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par atients undergoing limb amputation surgery are at risk of postoperative pain. Phantom limb pain (PLP) is a painful sensation referred to the absent limb after amputation; but it's not limited to the extremities, phantom pain has also been reported after loosing almost any body part, for example, nose, tongue or breast. \hyperref[b0]{1} The onset time of PLP varies from days to years, but it´s common to be experienced between the first 24 hours to one week after amputation. \hyperref[b0]{1} In longterm studies, it´s been observed a decrease in the frequency and duration of pain attacks over the years, which is accompanied by a decrement in its intensity, although in some cases, a worsening may occur. \hyperref[b1]{2,}\hyperref[b2]{3,}\hyperref[b3]{4} a) Etiology and risk factors for PLP Up to date, the exact reason that some patients develop PLP and others do not is unknown. It has been observed that its development is multifactorial, involving from peripheral, central and also psychological mechanisms. \hyperref[b4]{5} There is not a clear relationship between age or sex and the appearance of PLP in the literature, and it's more likely to appear when it's a bilateral amputation and how proximal it is. \hyperref[b5]{6} There are studies about the influence of previous pain on an extremity as a factor for the development of PLP. \hyperref[b5]{6,}\hyperref[b6]{7,}\hyperref[b7]{8} There are reports that more than 50\% of patients described PLP as similar to the pain they suffered before amputation. \hyperref[b8]{9,}\hyperref[b9]{10} At our country, type 2 Diabetes is the most common pathology causing amputation, referred as vascular diseases, it contributes to 81\% of cases. On the other hand, traumatic amputations represent 16\%, tumors, and congenital diseases account for 3\%. \hyperref[b10]{11} \section[{b) Pathophysiology}]{b) Pathophysiology}\par We may assume that PLP is an example of neuropathic pain since it occurs mainly as a result of an attempt to reorganize the nervous system followed by the deference of all sensory information involving amputation with nerve section.\par There are three mechanisms involved: "peripheral" given by the massive lesion discharge and the loss of nerve impulses towards the spinal cord. \hyperref[b11]{12} "spinal" Experimental studies have provided evidence of structural, physiological and neurochemical changes in the deferential neurons of the medullary dorsal horn. And it also causes alterations in "central" processing like transneuronal changes at the level of the nucleus of the thalamus. \hyperref[b0]{1,}\hyperref[b12]{13} There are many pharmacological therapies to treat PLP once it appears, and some others are trying to prevent it, without consistent results that allow us to have a standardized treatment regimen. Madabhushi et al. Made a case report of a patient undergoing femoral supracondylar amputation, using bupivacaína (local anesthetic) and clonidine (?2 agonist) with excellent results, the patient didn´t report any pain in the stump and neither PLP 12 months after surgery. \hyperref[b13]{14} There are also systematic reviews about the use of dexmedetomidine (?2 agonist) as an adjuvant to the local anesthetic for neuraxial and peripheral nerve blocks, to prolong the duration of analgesia compared to local anesthetic only. Cataloging Dexmedetomidine as a potential adjuvant and with more favorable pharmacodynamic and safety profile than Clonidine. \hyperref[b14]{15,}\hyperref[b16]{16} Due the incidence of chronic pain or symptoms related to phantom limb, which may determine disability, a very poor quality of life by the dependence on consumption of opioid and non-opioid analgesics or neuropathic medications to decrease pain, we proposed preventive analgesia in this case, consisting in the application of an anesthetic and analgesic before the surgical incision of the sciatic nerve with the mainly aim to reduce the magnitude and duration of acute postoperative pain and so, assess the appearance or not of PLP, which it implies a decrease in morbidity and improvement in the quality of life; benefiting the patient, family and health institutions. \section[{II.}]{II.} \section[{Materials and Methods}]{Materials and Methods}\par We carried out this study in Guadalajara´s Civil Hospital ¨Fray Antonio Alcalde¨, México. Our study was a controlled, simple randomized, double-blind, clinical trial, conducted within a period of one year, from January 2018 to January 2019.\par Inclusion criteria: Adult patients, scheduled for femoral supracondylar amputation, being due to traumatic cause, chronic disease and malignant tumor. Neuraxial block as anesthetic technique. American Society of Anesthesiologists´s physical status I-III. With signed informed consent. The exclusion criteria were: Refusal of the patient to participate, allergies known to any of the medications used, chronic hepatopathy disease, chronic renal disease, branch block or bradycardia and coagulation disorders.\par Sample size calculation. We considered the total supracondylar amputations (110) performed at the Guadalajara´s Civil Hospital during 2017, and established a significance level of 5\% (0.05) and a statistical power of 80\%. We obtained a total of 30 patients (15 per group).\par RD Group. Perineural administration of 0.5\% ropivacaine 10 ml adding dexmedetomidine 50 mcg, and maintenance with perineural catheter infusion connected to an elastomeric pump with 0.15\% ropivacaine for 24 hours.\par RS Group. Perineural administration of 0.5\% ropivacaine 10 ml adding 0.5 ml saline solution 0.9\%, and maintenance with perineural catheter infusion connected to an elastomeric pump with 0.15\% ropivacaine for 24 hours.\par Prior authorization by the Ethics and Research Committee of our Hospital, we assigned the patients in two groups randomly per sealed envelope.\par Anxiolysis was given if required, with IV Midazolam 30 mcg/kg. Antibiotic prophylaxis with Cephalothin 1 gr IV. Preemptive analgesia with Paracetamol 1 gr IV. Subarachnoid neuraxial block was administered, using hyperbaric bupivacaine 30 mcg/kg and intraoperative analgesia Parecoxib 40 mg IV.\par After dissection by the surgical team and before the section of the sciatic nerve, they identified the perineurium and infiltrated 10 ml of 0.5\% ropivacaine + 50 mcg dexmedetomidine (RD Group) or 0.5\% ropivacaine + 0.9\% saline solution (0.5 ml). We asked the surgeon to wait 5 minutes before performing the sciatic nerve section. After the amputation of the pelvic limb and before the surgical team closed by planes, a perineural catheter (20 G) was placed and laterally exteriorized through a separate skin incision, connected to an elastomeric pump with 0.15\% ropivacaine was placed in both groups for 24 hours.\par We measured heart rate, blood pressure, sedation level (Ramsay Scale), at the end of the procedure, at PACU (Post-Anesthesia Care Unit), 8 hours, and up to 24 hours after. Also we recorded the pain in the stump, phantom pain using VAS (Visual Analogue Scale) in case of presenting at PACU, 8 hours, 24 hours, 30 days and up to 3 months after the surgery, all patients were followed by phone call after discharge from hospital. We recorded the rescue analgesia, and it was given with tramadol 1mg/kg when VAS > 4. We also monitored side and adverse effects associated with the use of dexmedetomidine such as bradycardia, hypotension, nausea, vomiting, and respiratory depression in PACU, 1 hour, 8, and 24 hours postoperatively.\par We used the Statistical Package for the Social Sciences version 21 \hyperref[b17]{17} for statistical analysis. \section[{III.}]{III.} \section[{Results}]{Results}\par During January 2018 to January 2019, there were included 30 patients (15 per group) scheduled for supracondylar femoral amputation at our Hospital, under the anesthetic technique of subarachnoid block and perineural block of the sciatic nerve, which met the inclusion criteria from the study.\par According to demographic data, of the 15 patients in the RD group were 2 women (13\%) and 13 men (87\%) with a mean age of 57.4 years (SD 20.7). We classified them according to physical status in ASA I: 1 patient (7\%), ASA II: 1 patient (7\%), ASA 3: 13 patients (86\%), with the following preoperative diagnoses: diabetes mellitus 60\%, arterial occlusion 27\%, cancer 7\%, electric burn 7\%.\par Of the 15 patients in the RS group, were seven women (47\%) and eight men (53\%) with a mean age of 60 years (SD 17.4). We classified them according to physical status in ASA I: 2 patients (13\%), ASA II: 1 patient (7\%), ASA 3: 12 patients (80\%), with the following diagnoses: diabetes mellitus 53\%, arterial occlusion 33 \%, cancer 7\%, fracture exposed 7\%. (Table \hyperref[tab_0]{1}). During the postoperative period, both groups were evaluated for pain intensity, both at rest and in movement, of the stump and phantom limb, from PACU, at 8 hours, 24 hours, 30 days, and up to 3 months. Pain values with VAS 4 and above, had the prescription of rescue with Tramadol at 1mg / kg. In the RD group, at 8 hours, five patients required Tramadol, at 24 hours four patients, and 48 hours 2 of them. In the RS group at 8 hours, nine patients were given tramadol rescue, at 24 hours fourteen patients, and at 48 hours, 7 of them. Then it is possible to demonstrate with statistical significance that the perineural administration of dexmedetomidine does reduce the postoperative opioid requirements. (Table \hyperref[tab_2]{3}, Graph 2). Abbreviations: RD (Ropivacaine + Dexmedetomidine), RS (Ropivacaine + Saline Solution).\par We evaluated the appearance of phantom limb pain at rest and movement, which was not reported by any patient of the RD group from the moment of evaluation at PACU up to 3 months of follow-up. It is worth mentioning that two patients of the RD group presented prior amputation, one by contralateral first toe, and another ipsilateral transtibial, none reported previous phantom limb pain.\par From the RS group, up to 30 days, one patient reported mild phantom limb pain and one more patient moderate resting pain; on movement three patients reported mild pain at 30 days and only one patient mild pain at 3 months, who we referred to the Hospital Pain Clinic for evaluation and treatment. Without being these statistically significant values. (Table \hyperref[tab_3]{4}) We decided to measure the possible side effects of perineurally administered medications on systemic blood pressure and heart rate in PACU, as well as the level of sedation (Ramsay scale) and oxygen saturation in PACU up to 24 hours after surgery.\par We didn´t find statistically significant differences in the values of systemic blood pressure, heart rate, and oxygen saturation after the intervention. About sedation in the postoperative care unit, we found significant difference (p <0.025) with a higher degree of sedation in the RD group with an average of 2.8 on the Ramsay scale. 2.4 in the RS group. Of the possible adverse effects of the drugs used in our study, dizziness, nausea, vomiting, headache, and blurred vision were evaluated the first 24 hours after the perineural block. It was observed mainly in the RD group, dizziness in 13\% at 8 hours, against 7\% in the RS group (p = 0.068). Nausea in 13\% at 8 hours in both groups. And headache 13\% in the RD group against 20\% in the RS group at 8 hours (p = 0.62). However, we didn´t find statistically significant difference for any of the adverse effects measured.\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{figure2}}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-3.png} \caption{\label{figure3}}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-4.png} \caption{\label{figure4}}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.1798076923076923\textwidth}P{0.30240384615384613\textwidth}P{0.2901442307692308\textwidth}P{0.07764423076923076\textwidth}} Variable\tabcellsep RD Group. Ropivacaína + Dexmedetomidina. N=15\tabcellsep RS Group. Ropivacaína + Solución Salina. N=15\tabcellsep P (CI 95\%)\\ \tabcellsep (Mean ± SD)\tabcellsep (Mean ± SD)\tabcellsep \\ Edad\tabcellsep 57.4 ± 20.7\tabcellsep 60 ± 17.4\tabcellsep 0.56\\ Género\tabcellsep \tabcellsep \tabcellsep \\ Masculino\tabcellsep 13\tabcellsep 8\tabcellsep \\ Femenino\tabcellsep 2\tabcellsep 7\tabcellsep \\ ASA\tabcellsep \tabcellsep \tabcellsep 0.83\\ I\tabcellsep 1\tabcellsep 2\tabcellsep \\ II\tabcellsep 1\tabcellsep 1\tabcellsep \\ III\tabcellsep 13\tabcellsep 12\tabcellsep \end{longtable} \par {\small\itshape [Note: Statistical significance when obtaining P <0.05. Abbreviations: N (patients per group); ASA (Classification by the American Society of Anesthesiology); SD (Standard Deviation).]} \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.1090909090909091\textwidth}P{0.15227272727272725\textwidth}P{0.19999999999999998\textwidth}P{0.2590909090909091\textwidth}P{0.12954545454545455\textwidth}} \multicolumn{2}{l}{Variables Evaluated Period}\tabcellsep RD Group N = 15\tabcellsep RS Group N = 15\tabcellsep p (CI 95\%)\\ Pain Level\tabcellsep \tabcellsep \multicolumn{2}{l}{(Main ± SD) (Main ± SD)}\tabcellsep \\ Rest\tabcellsep PACU\tabcellsep 0\tabcellsep 0.13 ± 0.35\tabcellsep 0.143\\ \tabcellsep 8 hrs.\tabcellsep 0.93 ± 0.59\tabcellsep 1.2 ± 0.67\tabcellsep 0.426\\ \tabcellsep 24 hrs.\tabcellsep 0.73 ± 0.59\tabcellsep 1.60 ± 0.63\tabcellsep 0.003\\ \tabcellsep 30 days\tabcellsep 0\tabcellsep 0.33 ± 0.61\tabcellsep 0.099\\ \tabcellsep 3 months.\tabcellsep 0\tabcellsep 0.06 ± 0.25\tabcellsep 0.303\\ Movement\tabcellsep PACU\tabcellsep 0\tabcellsep 0.20 ± 0.41\tabcellsep 0.068\\ \tabcellsep 8 hrs.\tabcellsep 1.40 ± 0.73\tabcellsep 1.60 ± 0.73\tabcellsep 0.066\\ \tabcellsep 24 hrs.\tabcellsep 1.33 ± 0.48\tabcellsep 1.73 ± 0.45\tabcellsep 0.022\\ \tabcellsep 30 days.\tabcellsep 0\tabcellsep 0.33 ± 0.72\tabcellsep 0.189\\ \tabcellsep 3 months.\tabcellsep 0\tabcellsep 0\tabcellsep -\end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.36845493562231757\textwidth}P{0.1313304721030043\textwidth}P{0.1568669527896996\textwidth}P{0.09484978540772533\textwidth}P{0.09849785407725321\textwidth}} Variables\tabcellsep Evaluated period\tabcellsep RD Grup N = 15\tabcellsep RS Grup N = 15\tabcellsep p (CI 95\%)\\ Tramadol rescue.\tabcellsep \tabcellsep \multicolumn{2}{l}{Percent. Percent.}\tabcellsep \\ \tabcellsep 8 hrs.\tabcellsep 33\%\tabcellsep 60\%\tabcellsep 0.143\\ \tabcellsep 24 hrs.\tabcellsep 27\%\tabcellsep 93\%\tabcellsep 0.0002\\ \tabcellsep 48 hrs.\tabcellsep 13\%\tabcellsep 47\%\tabcellsep 0.046\\ \multicolumn{5}{l}{Statistical significance when obtaining P <0.05. Abbreviations: hrs (hours).}\end{longtable} \par \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.14890510948905109\textwidth}P{0.23576642335766423\textwidth}P{0.14890510948905109\textwidth}P{0.20164233576642335\textwidth}P{0.11478102189781021\textwidth}} \multicolumn{2}{l}{Variables Evaluated period}\tabcellsep RD Group N = 15\tabcellsep RS Group N = 15\tabcellsep p (CI 95\%)\\ Pain Score\tabcellsep \tabcellsep \multicolumn{2}{l}{(Main ± SD) (Main ± SD)}\tabcellsep \\ Rest\tabcellsep PACU\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 8 hrs.\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 24 hrs.\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 30 days.\tabcellsep 0\tabcellsep 0.20 ± 0.56\tabcellsep 0.343\\ \tabcellsep Three Months.\tabcellsep 0\tabcellsep 0.13 ± 0.51\tabcellsep 0.309\\ Movement\tabcellsep PACU\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 8 hrs.\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 24 hrs.\tabcellsep 0\tabcellsep 0\tabcellsep -\\ \tabcellsep 30 days.\tabcellsep 0\tabcellsep 0.20 ± 0.41\tabcellsep 0.068\\ \tabcellsep Three months.\tabcellsep 0\tabcellsep 0.06 ± 0.25\tabcellsep 0.309\end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{P{0.3615451388888889\textwidth}P{0.08559027777777778\textwidth}P{0.16822916666666665\textwidth}P{0.16527777777777777\textwidth}P{0.06935763888888889\textwidth}} \tabcellsep \tabcellsep RD Group\tabcellsep RS Group\tabcellsep \\ Variables\tabcellsep Evaluated Period\tabcellsep N = 15\tabcellsep N = 15\tabcellsep p (CI 95\%)\\ \tabcellsep \tabcellsep (Main ± SD)\tabcellsep (Main ± SD)\tabcellsep \\ Mean arterial pressure (mmHg)\tabcellsep PACU\tabcellsep 82.9 ± 13.12\tabcellsep 83.5 ± 12.04\tabcellsep 0.341\\ Heart rate (Bpm)\tabcellsep PACU\tabcellsep 75.2 ± 10.56\tabcellsep 74.0 ± 8.4\tabcellsep 0.555\\ Pulse-oximetry (\%)\tabcellsep PACU\tabcellsep 96.4 ± 2.02\tabcellsep 95.7 ± 1.90\tabcellsep 0.552\\ \tabcellsep 8 hrs.\tabcellsep 94.93 ± 0.96\tabcellsep 95.33 ± 0.72\tabcellsep 0.261\\ \tabcellsep 24 hrs.\tabcellsep 94.86 ± 0.80\tabcellsep 95.06 ± 0.59\tabcellsep 0.057\\ Sedation (Ramsay)\tabcellsep PACU\tabcellsep 2.80 ± 0.41\tabcellsep 2.40 ± 0.50\tabcellsep 0.025\\ \tabcellsep 8 hrs.\tabcellsep 2.20 ± 0.41\tabcellsep 2.00 ± 0.41\tabcellsep 0.068\\ \tabcellsep 24 hrs.\tabcellsep 2.00 ± 0\tabcellsep 2.00 ± 0\tabcellsep -\\ \multicolumn{5}{l}{Statistical significance when obtaining P <0.05. Abbreviations: N (patients per group); SD(Standard}\\ \multicolumn{2}{l}{deviation), PACU (PostAnesthetic Care Unit) hrs (hours).}\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_4}Table 5 :}\end{figure} \backmatter \subsection[{Discussion}]{Discussion}\par This study yielded significant data regarding the analgesic intervention of perineural infiltration with the combination of a local anesthetic (Ropivacaine) and an ?2 agonist (Dexmedetomidine) since in the published literature there are only isolated reports of clinical cases of this combination, but no clinical trials and much less meta-analysis; there are some others of perineural infiltration with local anesthetic without additive for the prevention of PLP, and other about the addition of an ?2 agonist for prolongation of peripheral nerve block, without assessing the impact on the prevention of phantom limb pain after amputation objectively.\par Regarding the levels of postoperative pain, at 24 hours lower scores of pain at rest were found using the combination ropivacaine + dexmedetomidine (p = 0.003); However, both interventions evaluated in this study with infiltration of local anesthetic and its postoperative infusion by using an elastomeric pump were effective for pain management, coinciding with the study by Borgh et al. In which they conclude that the use of a prolonged postoperative perineural perfusion of 0.5\% ropivacaine is effective therapy for the treatment of phantom limb pain. \hyperref[b18]{18} Therefore, postoperative opioid consumption was also reduced as described by Bosanquet et al. in a systematic review and meta-analysis on the use of intraoperative placed perineural catheter with infusion of local postoperative anesthetic \hyperref[b19]{19} . In this case, for our study, the addition of dexmedetomidine to perineural infiltration had a statistically significant difference in the reduction of the use of rescue tramadol at 24 hours, V. \subsection[{Conclusion}]{Conclusion}\par Phantom limb pain, associated with the amputation of a member of the organism, is a frequent complication after each procedure, sometimes reported with very high incidence rates.\par In the understanding of the pathophysiology for the development of this neuropathic pain, there were proposed different interventions for its treatment, but few focused on preventing its onset. One of those proposals is perineural infiltration and continuous infusion of local anesthetic adding an adjuvant to mitigate peripheral sensitization in nociceptors at the medullary level and central de-centralization (cortex and thalamus) in a preventive manner, avoiding the development of the PLP, which once it appears is very complex to treat.\par In this study, we corroborate and verified the advantages of doing a preventive intervention as described with a local anesthetic but adding an ?2 agonist, observing excellent results, and with no significant side effects. \subsection[{Financial support and sponsorship Nil. Conflicts of interest}]{Financial support and sponsorship Nil. Conflicts of interest}\par There are no conflicts of interest. \begin{bibitemlist}{1} \bibitem[ British Journal of Anaesthesia ()]{b15}\label{b15} \textit{}, \textit{British Journal of Anaesthesia} 2013. 110 (6) p. . \bibitem[Vázquez ()]{b10}\label{b10} \textit{Academia Nacional de Medicina. Los amputados, un reto para el Estado. Acta de la sesión del 4 de marzo del}, E Vázquez . 2015. \bibitem[Ehde and Czernieki ()]{b3}\label{b3} ‘Chronic pantom sensarions, phantom pain, residual limb pain and other regional pain after lower limb amputation’. D Ehde , J Czernieki . \textit{Arch Phys Med Rehabil} 2000. 81 p. . \bibitem[Abdallah and Brull]{b14}\label{b14} \textit{Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis}, F Abdallah , R Brull . \bibitem[Ibm Corp ()]{b17}\label{b17} \textit{IBM SPSS Statistics for Windows, Version 21.0}, Ibm Corp . 2012. Armonk, NY: IBM Corp. \bibitem[Jensen et al. ()]{b1}\label{b1} ‘Inmediate and long-term phantom limb pain in amputee: incidente, clinical charasteristics and relationship to preamputation limb pain’. T Jensen , B Krebs , P Rasmussen . \textit{Pain} 1985. 21 p. . \bibitem[Jensen et al. ()]{b8}\label{b8} ‘Inmediate and long-term phantom limb pain in amputee: incidente, clinical charasteristics and relationship to preamputation limb pain’. T Jensen , B Krebs , P Rasmussen . \textit{Pain} 1985. 21 p. . \bibitem[Nystrom and Hagbarth ()]{b12}\label{b12} ‘Microelectrode recordings from transected nerves in amputees with PLP’. B Nystrom , K E Hagbarth . \textit{Neurosci Lett} 1981. 27 p. . \bibitem[Katz and Melzack ()]{b7}\label{b7} ‘Pain memories in phantom limbs: review and clinical observations’. J Katz , R Melzack . \textit{Pain} 1990. 43 p. . \bibitem[Davis ()]{b5}\label{b5} ‘Pantom sensation, phantom pain and stump pain’. R Davis . \textit{Arch Phys Med Rehabil} 1993. 74 p. . \bibitem[El-Boghdadly ()]{b16}\label{b16} \textit{Perineural dexmedetomidine is more effective than clonidine when added to local anesthetic for supraclavicular brachial plexus block: A systematic Review and meta-analysis. Regional Anesthesia and Acute Pain Medicine}, El-Boghdadly . 2017. 124 p. 6. \bibitem[Luo and Anderson ()]{b0}\label{b0} ‘Phantom Limb Pain: A review’. Y Luo , T Anderson . \textit{International Anesthesiology Clinics} 2016. 54 p. . \bibitem[Weeks et al. ()]{b4}\label{b4} ‘Phantom limb pain: theories and therapies’. S R Weeks , V C Anderson-Barnes , J W Tsao . \textit{Neurologist} 2010. 16 p. . \bibitem[Jensen et al. ()]{b9}\label{b9} ‘Phantom limb, phantom pain and stump pain in amputees during the first 6 month following limb amputation’. T Jensen , B Krebs , J Nielsen , P Rasmussen . \textit{Pain} 1983. 17 p. . \bibitem[Weinstein ()]{b11}\label{b11} ‘Phantom pain’. S Weinstein . \textit{Oncology} 1994. 8 p. . \bibitem[Dijkstra et al. ()]{b2}\label{b2} ‘Phantom pain and risk factors: A multivariate analisis’. P Dijkstra , H Geertzen , R Stewart . \textit{J of Pain and Sym Manag} 2002. 24 p. . \bibitem[Bosanquet and Glasbey ()]{b19}\label{b19} ‘Systematic review and meta-analysis of the efficacy of perineural local anaesthetic catheters after major lower limb amputation’. D Bosanquet , J Glasbey . \textit{Eur J Vasc Endovasc Surg} 2015. 50 p. . \bibitem[Madabhushi and Reuben ()]{b13}\label{b13} ‘The efficacy of postoperative perineural infusion of bupivacaine and clonidine after lower extremity amputation in preventing phantom limb and stump pain’. L Madabhushi , S Reuben . \textit{Journal of Clinical Anesthesia} 2007. 19 p. . \bibitem[Nikolajsen and Corner ()]{b6}\label{b6} ‘The influence of preamputation pain on postamputation stump and phantom pain’. L Nikolajsen , K Corner . \textit{Pain} 1997. 72 p. . \bibitem[Borghi and D´addabbo ()]{b18}\label{b18} ‘The use of prolonged peripheral neural blockade after lower extremity amputation: the effect on symptoms associated with phantom limb syndrom’. B Borghi , M D´addabbo . \textit{Rev Anesthesia and Analgesia} 2010. 111 p. 5. \end{bibitemlist} \end{document}